Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Annexin A12-26 Treatment Improves Skin Heterologous Transplantation by Modulating Inflammation and Angiogenesis Processes.

Lacerda JZ, Drewes CC, Mimura KKO, Zanon CF, Ansari T, Gil CD, Greco KV, Farsky SHP, Oliani SM.

Front Pharmacol. 2018 Sep 10;9:1015. doi: 10.3389/fphar.2018.01015. eCollection 2018.

2.

Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.

Zampini M, Tregnago C, Bisio V, Simula L, Borella G, Manara E, Zanon C, Zonta F, Serafin V, Accordi B, Campello S, Buldini B, Pession A, Locatelli F, Basso G, Pigazzi M.

Leukemia. 2018 May;32(5):1124-1134. doi: 10.1038/s41375-017-0003-y. Epub 2018 Feb 2.

PMID:
29472719
3.

TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy.

Aveic S, Corallo D, Porcù E, Pantile M, Boso D, Zanon C, Viola G, Sidarovich V, Mariotto E, Quattrone A, Basso G, Tonini GP.

Eur J Pharmacol. 2018 Jan 5;818:435-448. doi: 10.1016/j.ejphar.2017.11.016. Epub 2017 Nov 14.

PMID:
29154838
4.

Transcription instability in high-risk neuroblastoma is associated with a global perturbation of chromatin domains.

Zanon C, Tonini GP.

Mol Oncol. 2017 Nov;11(11):1646-1658. doi: 10.1002/1878-0261.12139. Epub 2017 Oct 10.

5.

miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.

D'Angelo E, Zanon C, Sensi F, Digito M, Rugge M, Fassan M, Scarpa M, Pucciarelli S, Nitti D, Agostini M.

J Clin Pathol. 2018 Apr;71(4):344-350. doi: 10.1136/jclinpath-2017-204690. Epub 2017 Sep 4.

PMID:
28870889
6.

Isolation and characterization of cellulose nanofibers from cassava root bagasse and peelings.

Leite ALMP, Zanon CD, Menegalli FC.

Carbohydr Polym. 2017 Feb 10;157:962-970. doi: 10.1016/j.carbpol.2016.10.048. Epub 2016 Oct 18.

7.

The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.

Chieregato K, Zanon C, Castegnaro S, Bernardi M, Amati E, Sella S, Rodeghiero F, Astori G.

Blood Transfus. 2017 Jan;15(1):93-100. doi: 10.2450/2016.0263-15. Epub 2016 Mar 21.

8.

Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma.

D'Angelo E, Fassan M, Maretto I, Pucciarelli S, Zanon C, Digito M, Rugge M, Nitti D, Agostini M.

Oncotarget. 2016 May 10;7(19):28647-57. doi: 10.18632/oncotarget.8725.

9.

Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.

Lasorsa VA, Formicola D, Pignataro P, Cimmino F, Calabrese FM, Mora J, Esposito MR, Pantile M, Zanon C, De Mariano M, Longo L, Hogarty MD, de Torres C, Tonini GP, Iolascon A, Capasso M.

Oncotarget. 2016 Apr 19;7(16):21840-52. doi: 10.18632/oncotarget.8187.

10.

Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.

Aveic S, Pantile M, Seydel A, Esposito MR, Zanon C, Li G, Tonini GP.

Oncotarget. 2016 Feb 2;7(5):5646-63. doi: 10.18632/oncotarget.6778.

11.

An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer.

Agostini M, Janssen KP, Kim IJ, D'Angelo E, Pizzini S, Zangrando A, Zanon C, Pastrello C, Maretto I, Digito M, Bedin C, Jurisica I, Rizzolio F, Giordano A, Bortoluzzi S, Nitti D, Pucciarelli S.

Oncotarget. 2015 Oct 20;6(32):32561-74. doi: 10.18632/oncotarget.4935.

12.

A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients.

Agostini M, Zangrando A, Pastrello C, D'Angelo E, Romano G, Giovannoni R, Giordan M, Maretto I, Bedin C, Zanon C, Digito M, Esposito G, Mescoli C, Lavitrano M, Rizzolio F, Jurisica I, Giordano A, Pucciarelli S, Nitti D.

Cancer Biol Ther. 2015;16(8):1160-71. doi: 10.1080/15384047.2015.1046652. Epub 2015 May 29.

13.

Mutational profiling of kinases in glioblastoma.

Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, Bardelli A.

BMC Cancer. 2014 Sep 26;14:718. doi: 10.1186/1471-2407-14-718.

14.

The importance of personality and parental styles on optimism in adolescents.

Zanon C, Bastianello MR, Pacico JC, Hutz CS.

Span J Psychol. 2014;17:E47. doi: 10.1017/sjp.2014.49.

PMID:
25012150
15.

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, Wesseling P, Hulsebos TJ, Troost D, van Tilborg AA, Leenstra S, Vandertop WP, Bardelli A, van Noorden CJ, Bleeker FE.

Neuro Oncol. 2014 Sep;16(9):1263-73. doi: 10.1093/neuonc/nou005. Epub 2014 Feb 6.

16.

Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells.

Zanon C, Stocchero M, Albiero E, Castegnaro S, Chieregato K, Madeo D, Rodeghiero F, Astori G.

Cytometry B Clin Cytom. 2014 Jul;86(4):257-62. doi: 10.1002/cyto.b.21124. Epub 2013 Sep 3.

17.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S.

Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2.

18.

MoMA-LigPath: a web server to simulate protein-ligand unbinding.

Devaurs D, Bouard L, Vaisset M, Zanon C, Al-Bluwi I, Iehl R, Siméon T, Cortés J.

Nucleic Acids Res. 2013 Jul;41(Web Server issue):W297-302. doi: 10.1093/nar/gkt380. Epub 2013 May 13.

19.

A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: Implication for their in-vivo use.

Chieregato K, Albiero E, Castegnaro S, Bernardi M, d'Amore ES, Zanon C, Madeo D, Rodeghiero F, Astori G.

Blood Cells Mol Dis. 2012 Oct 15-Dec 15;49(3-4):159-65. doi: 10.1016/j.bcmd.2012.05.009. Epub 2012 Jul 19.

PMID:
22818859
20.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A.

Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.

21.

Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines.

Castegnaro S, Visco C, Chieregato K, Bernardi M, Albiero E, Zanon C, Madeo D, Rodeghiero F.

Leuk Lymphoma. 2012 Nov;53(11):2262-8. doi: 10.3109/10428194.2012.688200. Epub 2012 May 21.

PMID:
22530665
22.

The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.

Visco C, Castegnaro S, Chieregato K, Bernardi M, Albiero E, Zanon C, Madeo D, Rodeghiero F.

Blood Cells Mol Dis. 2012 Jan 15;48(1):68-75. doi: 10.1016/j.bcmd.2011.09.007. Epub 2011 Oct 28.

PMID:
22036761
23.

Identification of low-frequency variants associated with gout and serum uric acid levels.

Sulem P, Gudbjartsson DF, Walters GB, Helgadottir HT, Helgason A, Gudjonsson SA, Zanon C, Besenbacher S, Bjornsdottir G, Magnusson OT, Magnusson G, Hjartarson E, Saemundsdottir J, Gylfason A, Jonasdottir A, Holm H, Karason A, Rafnar T, Stefansson H, Andreassen OA, Pedersen JH, Pack AI, de Visser MC, Kiemeney LA, Geirsson AJ, Eyjolfsson GI, Olafsson I, Kong A, Masson G, Jonsson H, Thorsteinsdottir U, Jonsdottir I, Stefansson K.

Nat Genet. 2011 Oct 9;43(11):1127-30. doi: 10.1038/ng.972.

PMID:
21983786
24.

European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.

Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, Witjes JA, Grotenhuis AJ, Verhaegh GW, Hulsbergen-van de Kaa CA, Besenbacher S, Gudbjartsson D, Stacey SN, Gudmundsson J, Johannsdottir H, Bjarnason H, Zanon C, Helgadottir H, Jonasson JG, Tryggvadottir L, Jonsson E, Geirsson G, Nikulasson S, Petursdottir V, Bishop DT, Chung-Sak S, Choudhury A, Elliott F, Barrett JH, Knowles MA, de Verdier PJ, Ryk C, Lindblom A, Rudnai P, Gurzau E, Koppova K, Vineis P, Polidoro S, Guarrera S, Sacerdote C, Panadero A, Sanz-Velez JI, Sanchez M, Valdivia G, Garcia-Prats MD, Hengstler JG, Selinski S, Gerullis H, Ovsiannikov D, Khezri A, Aminsharifi A, Malekzadeh M, van den Berg LH, Ophoff RA, Veldink JH, Zeegers MP, Kellen E, Fostinelli J, Andreoli D, Arici C, Porru S, Buntinx F, Ghaderi A, Golka K, Mayordomo JI, Matullo G, Kumar R, Steineck G, Kiltie AE, Kong A, Thorsteinsdottir U, Stefansson K, Kiemeney LA.

Hum Mol Genet. 2011 Nov 1;20(21):4268-81. doi: 10.1093/hmg/ddr303. Epub 2011 Jul 12.

25.

Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.

Riera L, Lasorsa E, Bonello L, Sismondi F, Tondat F, Di Bello C, Di Celle PF, Chiarle R, Godio L, Pich A, Facchetti F, Ponzoni M, Marmont F, Zanon C, Bardelli A, Inghirami G.

Leuk Lymphoma. 2011 Sep;52(9):1742-50. doi: 10.3109/10428194.2011.574757. Epub 2011 May 23.

26.

A rare variant in MYH6 is associated with high risk of sick sinus syndrome.

Holm H, Gudbjartsson DF, Sulem P, Masson G, Helgadottir HT, Zanon C, Magnusson OT, Helgason A, Saemundsdottir J, Gylfason A, Stefansdottir H, Gretarsdottir S, Matthiasson SE, Thorgeirsson GM, Jonasdottir A, Sigurdsson A, Stefansson H, Werge T, Rafnar T, Kiemeney LA, Parvez B, Muhammad R, Roden DM, Darbar D, Thorleifsson G, Walters GB, Kong A, Thorsteinsdottir U, Arnar DO, Stefansson K.

Nat Genet. 2011 Mar 6;43(4):316-20. doi: 10.1038/ng.781.

27.

Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk.

Rafnar T, Sulem P, Besenbacher S, Gudbjartsson DF, Zanon C, Gudmundsson J, Stacey SN, Kostic JP, Thorgeirsson TE, Thorleifsson G, Bjarnason H, Skuladottir H, Gudbjartsson T, Isaksson HJ, Isla D, Murillo L, García-Prats MD, Panadero A, Aben KK, Vermeulen SH, van der Heijden HF, Feser WJ, Miller YE, Bunn PA, Kong A, Wolf HJ, Franklin WA, Mayordomo JI, Kiemeney LA, Jonsson S, Thorsteinsdottir U, Stefansson K.

Cancer Res. 2011 Feb 15;71(4):1356-61. doi: 10.1158/0008-5472.CAN-10-2852. Epub 2011 Feb 8.

28.

Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.

Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S, Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X, Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A, Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S, Shen CY, Wu PE, Försti A, Lenner P, Henriksson R, Johansson R, Enquist K, Hallmans G, Jonsson T, Sigurdsson H, Alexiusdottir K, Gudmundsson J, Sigurdsson A, Frigge ML, Gudmundsson L, Kristjansson K, Halldorsson BV, Styrkarsdottir U, Gulcher JR, Hemminki K, Lindblom A, Kiemeney LA, Mayordomo JI, Foekens JA, Couch FJ, Olopade OI, Gudbjartsson DF, Thorsteinsdottir U, Rafnar T, Johannsson OT, Stefansson K.

PLoS Genet. 2010 Jul 22;6(7):e1001029. doi: 10.1371/journal.pgen.1001029.

29.

A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.

Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, Gudbjartsson DF, Stacey SN, Gudmundsson J, Zanon C, Kostic J, Masson G, Bjarnason H, Palsson ST, Skarphedinsson OB, Gudjonsson SA, Witjes JA, Grotenhuis AJ, Verhaegh GW, Bishop DT, Sak SC, Choudhury A, Elliott F, Barrett JH, Hurst CD, de Verdier PJ, Ryk C, Rudnai P, Gurzau E, Koppova K, Vineis P, Polidoro S, Guarrera S, Sacerdote C, Campagna M, Placidi D, Arici C, Zeegers MP, Kellen E, Gutierrez BS, Sanz-Velez JI, Sanchez-Zalabardo M, Valdivia G, Garcia-Prats MD, Hengstler JG, Blaszkewicz M, Dietrich H, Ophoff RA, van den Berg LH, Alexiusdottir K, Kristjansson K, Geirsson G, Nikulasson S, Petursdottir V, Kong A, Thorgeirsson T, Mungan NA, Lindblom A, van Es MA, Porru S, Buntinx F, Golka K, Mayordomo JI, Kumar R, Matullo G, Steineck G, Kiltie AE, Aben KK, Jonsson E, Thorsteinsdottir U, Knowles MA, Rafnar T, Stefansson K.

Nat Genet. 2010 May;42(5):415-9. doi: 10.1038/ng.558. Epub 2010 Mar 28.

30.

Ramirez's abdominoplasty technique combined with intraperitoneal chemohyperthermia after surgical cytoreductive procedures for the treatment of advanced intraperitoneal cancer in patients with ventral hernia.

Fraccalvieri M, Simone P, Bruno F, Gaglia P, Ribero F, Scuderi S, Seghesio R, Monni M, Zanon C.

Ann Plast Surg. 2010 Feb;64(2):187-92. doi: 10.1097/SAP.0b013e3181a20b31.

PMID:
20098105
31.

Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.

Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, Benediktsdottir KR, Magnusdottir DN, Orlygsdottir G, Jakobsdottir M, Stacey SN, Sigurdsson A, Wahlfors T, Tammela T, Breyer JP, McReynolds KM, Bradley KM, Saez B, Godino J, Navarrete S, Fuertes F, Murillo L, Polo E, Aben KK, van Oort IM, Suarez BK, Helfand BT, Kan D, Zanon C, Frigge ML, Kristjansson K, Gulcher JR, Einarsson GV, Jonsson E, Catalona WJ, Mayordomo JI, Kiemeney LA, Smith JR, Schleutker J, Barkardottir RB, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K.

Nat Genet. 2009 Oct;41(10):1122-6. doi: 10.1038/ng.448. Epub 2009 Sep 20.

32.

Aggressive sebaceous carcinoma of the head.

Scuderi S, Giaccone M, D'Errico E, Maorenzic MA, Fontanellaa M, Castellano I, Zanon C, Gaetini AM.

Chir Ital. 2009 May-Jun;61(3):401-4.

PMID:
19694247
33.

Molecular profiling of the "plexinome" in melanoma and pancreatic cancer.

Balakrishnan A, Penachioni JY, Lamba S, Bleeker FE, Zanon C, Rodolfo M, Vallacchi V, Scarpa A, Felicioni L, Buck M, Marchetti A, Comoglio PM, Bardelli A, Tamagnone L.

Hum Mutat. 2009 Aug;30(8):1167-74. doi: 10.1002/humu.21017.

34.

Absence of AKT1 mutations in glioblastoma.

Bleeker FE, Lamba S, Zanon C, van Tilborg AA, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Bardelli A.

PLoS One. 2009 May 20;4(5):e5638. doi: 10.1371/journal.pone.0005638.

35.

Phase 0 trial as first human study in translational research in medical technology.

Zanon C.

Tumori. 2008 Jul-Aug;94(4):626-7. No abstract available.

PMID:
18822710
36.

AKT1(E17K) in human solid tumours.

Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Grammastro MD, Sciarrotta MG, Zanon C, Marchetti A, Bardelli A.

Oncogene. 2008 Sep 18;27(42):5648-50. doi: 10.1038/onc.2008.170. Epub 2008 May 26.

PMID:
18504432
37.

PIK3CA cancer mutations display gender and tissue specificity patterns.

Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D, Daidone MG, Pilotti S, Pierotti MA, Bardelli A.

Hum Mutat. 2008 Feb;29(2):284-8.

PMID:
18022911
38.

Past, present and future of long-term hepatic arterial accesses with implantable ports.

Aldrighetti L, Ferla G, Grosso M, Zanon C.

J Vasc Access. 2001 Jan-Mar;2(1):3-7. No abstract available.

PMID:
17638250
39.

Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.

Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, van Tilborg AA, Leenstra S, Zanon C, Bardelli A.

Cancer Res. 2007 Apr 15;67(8):3545-50.

40.

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A.

Cancer Res. 2007 Mar 15;67(6):2643-8.

41.

Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer.

Zanon C, Bortolini M, Chiappino I, Simone P, Bruno F, Gaglia P, Airoldi M, Deriu L, Mashiah A.

World J Surg. 2006 Nov;30(11):2025-32.

PMID:
17058031
42.

Intra-arterial hepatic chemotherapy: management of liver tumors by percutaneous port-a-cath positioning.

Grosso M, Scarrone A, Pedrazzini F, Priotto R, Testa F, Lingua G, Mondino I, Zanon C.

J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):171-5.

PMID:
16767926
44.

Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.

Airoldi M, Cattel L, Passera R, Pedani F, Milla P, Zanon C.

Pancreas. 2006 Jan;32(1):44-50.

PMID:
16340743
45.

Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer.

Frattini M, Signoroni S, Pilotti S, Bertario L, Benvenuti S, Zanon C, Bardelli A, Pierotti MA.

Cancer Res. 2005 Dec 1;65(23):11227. No abstract available.

46.

Anti-allergic properties of the bromeliaceae Nidularium procerum: inhibition of eosinophil activation and influx.

Vieira-de-Abreu A, Amendoeira FC, Gomes GS, Zanon C, Chedier LM, Figueiredo MR, Kaplan MA, Frutuoso VS, Castro-Faria-Neto HC, Weller PF, Bandeira-Melo C, Bozza PT.

Int Immunopharmacol. 2005 Dec;5(13-14):1966-74. Epub 2005 Jun 20.

PMID:
16275631
47.

Anti-inflammatory activity in the aqueous crude extract of the leaves of Nidularium procerum: A bromeliaceae from the Brazilian coastal rain forest.

Amendoeira FC, Frutuoso VS, Zanon C, Chedier LM, Figueiredo MR, Kaplan MA, Bandeira-Melo C, Bozza PT, Castro-Faria-Neto HC.

Biol Pharm Bull. 2005 Jun;28(6):1010-5.

48.

Major depression in patients with borderline personality disorder: a clinical investigation.

Bellino S, Patria L, Paradiso E, Di Lorenzo R, Zanon C, Zizza M, Bogetto F.

Can J Psychiatry. 2005 Mar;50(4):234-8.

PMID:
15898463
49.

[A double blind randomised clinical trial to assess the efficacy of the treatments of the superficial pressure sores].

Di Giulio P, Saiani L, Laquintana D, Palese A, Perli S, Andreatta M, Rosa F, Chini P, Soraperra F, Ventura I, Suriani C, Romani S, Zancarli M, Martini M, Partel F, Bassetti S, Kaisermann R, Bortolotti C, Gianordoli M, Rizzoli I, Nardelli R, Pellizzari E, Valduga E, Castaman M, Pordenon M, Beltrame M, Bertolo C, Casasola E, Del Pin P, Giolo S, Marcatti E, Pecini D, Rodaro M, Zanon C, Stefanon L, Covre L, Babbo C, Martin I, Roilo A, Zanutel M, Sabbadin S, Boin L, Caron A, Martignago E, Venturin V, Greggio A, Frigo P, Lazzaron D, Tonietto A, Zanin B, Zorzi S, Zuanon A, Salmaso D, Frison T, Marin I, Buosi A, Fiorese E, Gasparin D, Goat B, Saccardo G, Simonetto O, Gomiero S, Baccara N, Ghirardello L, Niolu M, Silvestri S, Buffon ML, Casson P, Santantonio R, Albore P, Mazzorana E, Terziariol L, Bulgarelli G, Barani E, Gasparini P, Migliori S, Sasso E, Marfisi RM, Tognoni G, Sgaroni G, Noro G, Mattiuzzo M; Gruppo PARI-ETLD.

Assist Inferm Ric. 2004 Oct-Dec;23(4):201-8. Italian. Erratum in: Assist Inferm Ric. 2005 Jan-Mar;24(1):51. Mattiuzzo, Mara [added].

PMID:
15709463
50.

Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer.

Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, Bruno F, De Riu L, Airoldi M, Pedani F.

World J Surg. 2004 Oct;28(10):1040-5. Epub 2004 Sep 29.

PMID:
15573262

Supplemental Content

Support Center